Stay updated on Losartan and Nivolumab in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Losartan and Nivolumab in Pancreatic Cancer Clinical Trial page.

Latest updates to the Losartan and Nivolumab in Pancreatic Cancer Clinical Trial page
- Check2 days agoChange DetectedRevision: v3.6.5 was added to the page, indicating an update to the study record. A large set of core trial details, including the listed interventions (Nivolumab, Losartan, FOLFIRINOX) and related MeSH terms, were removed from the study record, altering the displayed scope of the trial.SummaryDifference21%

- Check9 days agoNo Change Detected
- Check17 days agoChange DetectedRevision: v3.6.4 was added, replacing the previous Revision: v3.6.3 in the page's study record dates.SummaryDifference0.0%

- Check24 days agoChange DetectedNo changes were recorded for this page. The study overview, design, and eligibility criteria remain as published.SummaryDifference0.0%

- Check38 days agoChange DetectedThe study record revision was updated from v3.6.2 to v3.6.3, indicating a minor update to the page version. The change reflects an incremental update to the publicly posted record rather than substantive content changes.SummaryDifference0.0%

- Check45 days agoChange DetectedSite revision updated from v3.6.0 to v3.6.2, reflecting a backend platform update on the study page. No study details or navigation are affected.SummaryDifference0.0%

- Check59 days agoChange DetectedDifference0.4%

Stay in the know with updates to Losartan and Nivolumab in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Losartan and Nivolumab in Pancreatic Cancer Clinical Trial page.